











































































































































































































































































































































































































































































































































































































































































































Figure 1. Tumor-infiltrating NK cells controls tumor growth in IFN- γ-dependent manner.  
MCA205-Luc2 cells (105 cells/mouse) were s.c. inoculated into WT mice or IFN- γ KO mice. To 
deplete NK cells (NK dep), mice were treated with anti-asGM1 antibody (200 μg/mouse, i.p.) on 
Day -3 and -1 (Day 0=tumor inoculation). To deplete CD4 T cells (CD4 dep) and CD8 T cells 
(CD8 dep), mice were treated with anti-CD4 mAb (clone GK1.5, 250 μg/mouse, i.p.) or anti-CD8 
mAb (clone 53-6.7, 250 μg/mouse, i.p.) on Day -3 and -1, respectively. To block CXCR3, mice 
were treated with anti-CXCR3 mAb (clone CXCR3-173, 500 µg/mouse, i.p.) on Day -1, 0, 2, 4 
and 6. The bioluminescence of MCA205-Luc2 tumor was monitored in WT mice (A, B, C) or 
IFN-γ KO mice (B). Luminescence was normalized by that of the individual mouse on Day 0. 



























































































Figure 2. Requirement of IL-17A-Ly-6G+ neutrophil axis for enhanced tumor growth
in NK-cell depleted mice.
MCA205-Luc2 (A and B) or 3LL-Luc2 (C) cells (105 cells/mouse) were s.c. inoculated into WT 
mice or IL-17 KO mice. To deplete NK cells and/or neutrophils, mice were treated with 
anti-asGM1 antibody (200 μg/mouse, i.p.) on Day -3 and -1 (Day 0=tumor inoculation), and/or 
anti-Ly6G mAb (500 μg/mouse, i.p.) on Day -1 and 3, respectively. The bioluminescence of 
MCA205-Luc2 tumors was monitored. Luminescence was normalized by that of the individual 
mouse on Day 0. Data are presented as the mean ± SEM. *P < 0.05, **P < 0.01 compared 







































































Figure 3. Impaired tumor neutrophil infiltration in IL-17-deficient, but not 
in NK cell-depleted mice.
MCA205-Luc2 cells (105 cells/mouse) were s.c. inoculated subcutaneously into 
WT or IL-17 KO mice. To deplete NK cells, mice were treated with anti-asGM1 
antibody (200 μg/mouse, i.p.) on Day -3 and -1 (Day 0=tumor inoculation). (A) 
Dot plots of flow cytometry analysis are shown. The numbers are the percent-
age of cells electronically gated on neutrophils (CD11b+ Ly-6G+) in tumors. (B) 
Summary of percentage of neutrophils in tumors. Data are presented as the 



















































Figure 4. Characterization of tumor-infiltrating neutrophils in NK-depleted mice.
MCA205-Luc2 cells (105 cells/mouse) were inoculated subcutaneously into WT mice. To 
deplete NK cells, mice were treated with anti-asGM1 antibody (200 μg/mouse, i.p.) on Day 
-3 and -1 (Day 0=tumor inoculation). Tumor samples were harvested on day 7 and CD11b+ 
Ly-6G+ neutrophils were isolated by cell sorting. (A) Nucleus segmentation of neutrophils 
from control or NK cell-depleted (NK dep) mice is shown. (B) Relative mRNA expressions 
of neutrophils are shown. The data indicate normalized mRNA expression of neutrophils in 
NK cell-depleted mice to control mice. Data are presented as the mean ± SEM. *P < 0.05 









































































































Figure 5. NK cells control angiogenic switching of Ly6G+ tumor-infiltrating neutrophils. 
(A) Purified peritoneal Ly6G+ neutrophils were cultured with the supernatant of MCA205-Luc2 cells 
(cell culture), tumors from WT mice (control), or tumors from NK cell-depleted mice (NK dep) for 6 
hrs. (B) To block IFN-γ, anti-IFN-γ mAb (α-IFN-γ, 10 µg/ml) was added into the culture of peritoneal 
neutrophils with tumor supernatants. (C) Purified peritoneal Ly6G+ neutrophils were cultured with the 
supernatant of control tumors or NK cell-depleted tumors (NK dep) from WT or IFN-γ KO mice for 6 
hrs. Relative mRNA expressions of neutrophils are shown. The data indicate normalized mRNA 
expression of neutrophils cultured with MCA205-Luc2 cell supernatant. (D) MCA205-Luc2 cells (105) 
were s.c. inoculated into WT mice. Mice were treated with anti-asGM1 antibody (200 μg/mouse, i.p.) 
and/or treated with anti-Ly6G mAb (α-Ly6G, 500 μg/mouse, i.p.) on Day -1 and 3. Tumor samples 
were harvested on day 7 and cells were cultured for 24 hrs to collect the supernatant. The VEGF 
production was measured by ELISA. Data are presented as the mean ± SEM. *P < 0.05 compared 














































Figure 7. Ly6G+ neutrophil-VEGF axis controls tumor growth in NK-cell depleted mice.
MCA205-Luc2 cells (105 cells/mouse) were s.c. inoculated into WT mice. To deplete NK cells 
and/or neutrophils, mice were treated with anti-asGM1 antibody (200 μg/mouse, i.p.) on Day 
-3 and -1 (Day 0=tumor inoculation), and/or anti-Ly6G mAb (α-Ly6G, 500 μg/mouse, i.p.) on 
Day -1 and 3, respectively. Group of mice were treated with SU5416 (30 mg/kg i.p.) for 7 
days from the day of tumor inoculation. The bioluminescence of MCA205-Luc2 tumors was 
monitored. Luminescence was normalized by that of the individual mouse on Day 0. Data are 
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Figure 8. 5-FU-induced systemic neutropenia controls cancer cell proliferation in NK-cell 
depleted mice. 
MCA205-Luc2 cells (105 cells) were s.c. inoculated in WT mice (control) or NK cell-depleted 
mice (NK dep). Mice were treated with anti-asGM1 antibody (200 μg/mouse, i.p.) on Day -3 and 
-1 (Day 0=tumor inoculation) and/or 5-FU (150 mg/kg, i.v.) on Day 0. (A) Peripheral blood mono-
nuclear cells (PBMCs) were collected on day 7 and the dot plots (left) and summary (right) of 
flow cytometry analysis are shown. The numbers are the percentage of cells electronically gated 
on neutrophils (CD11b+ Ly-6G+) in PBMCs. (B) The bioluminescence of MCA205-Luc2 tumors 
was monitored. Luminescence was normalized by that of the individual mouse on Day 0. Data 
are presented as the mean ± SEM.  ** P < 0.01 compared with 5-FU untreated mice. 
Supplementary Figure 1. Characterization of MCA205-Luc2 cells.
(A) The graphs are plotted as luminescence (photons/second) against cell number of 
MCA205-Luc2 cells, and the linear correlation of the plots is shown as R2 (upper 
panel). MCA205-Luc2 cells were plated at the indicated cell number and luminescent 
images are shown (lower panel). (B) MCA205-Luc2 cells (105 cells) were s.c. inoculat-
ed into syngeneic C57BL/6 mice. Tumor growth monitored by bioluminescent imaging 
(open circle) or conventional caliper measurement (closed circle) is shown (upper 
panel). Images of bioluminescence on Day 0 to 5 after tumor inoculation are shown 
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Supplementary Figure 2. No alteration in the phenotype of tumor-infiltrated CTL.
MCA205-Luc2 cells (105) were s.c. inoculated into syngeneic C57BL/6 mice. Mice were treated with 
anti-asGM1 antibody (200 μg/mouse, i.p.) on Day -3 and -1 (Day 0=tumor inoculation) and/or 
treated with anti-Ly6G mAb (500 μg/mouse, i.p.) on Day -1 and 3. On Day 7, tumor-infiltrating 
lymphocytes were isolated and subjected to flow cytometry analysis. Representative dot plots of the 
expressions of CD44 and CD62L (A) or PD-1 (B) on electronically gated CD3+ CD8+ T cells in 
tumors are shown. The presented graphs show (A) the proportion of CD8 T cells and (B) the PD-1 
expression on CD8+ T (NK1.1- CD3+ CD8+) cells in tumor.
